专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003046166A1 SUIZIDGENSYSTEME 审中-公开
公开(公告)号：WO2003046166A1
公开(公告)日：2003-06-05
申请号：PCT/EP2002/012962
申请日：2002-11-19
申请人： KRAMM, Christof , HANENBERG, Helmut , GÖBEL, Ulrich
发明人： KRAMM, Christof , HANENBERG, Helmut , GÖBEL, Ulrich
IPC分类号： C12N9/12
CPC分类号： C12N15/86 , A61K48/00 , C12N9/0071 , C12N9/1211 , C12N9/93 , C12N2740/10043 , C12N2840/203 , C12Y114/14001
摘要： Die Erfindung betrifft Suizidgensysteme, besonders solche mit Herpes simplex Virus Typ 1 Thymidinkinase (HSV-tk), Cytochrom P450 Isoenzym 4B1 (cyp4B1) oder der humanen Folylpolyglutamatsynthase (fpgs), insbesondere auch in Kombination miteinander, sowie entsprechende DNA-Abschnitte, Vektoren, infektiöse Partikel, transfizierte Zellen und diese enthaltende Arzneimittel sowie die Verwendung der Gegenstände und Suizidgene auch in Kombination mit aktivierten Wirkstoffen zur Behandlung von Leukämie bzw. Graft-versus-Host-Reaktionen beispielsweise bei Spenderlymphozyten.
摘要翻译：胸苷本发明涉及自杀基因系统，特别是包含疱疹1单纯疱疹病毒型激酶（HSV-TK），细胞色素P450同工酶4B1（CYP4B1）或人folylpolyglutamates合酶（FPGS），特别是上述的在彼此组合和相应的DNA区段，载体，感染性颗粒，转染的细胞和药物含有上述。本发明还涉及到使用对象和自杀基因，所以与用于白血病或移植物宿主反应对于供体淋巴细胞实施例的治疗活性剂组合使用。

2. 发明申请

WO2013178635A1 CYTOCHROME P450 SUICIDE GENE SYSTEM 审中-公开
标题翻译： CYTOCHROME P450 SUICIDE基因系统
公开(公告)号：WO2013178635A1
公开(公告)日：2013-12-05
申请号：PCT/EP2013/060973
申请日：2013-05-28
申请人： HANENBERG, Helmut
发明人： HANENBERG, Helmut , WIEK, Constanze , KRAMM, Christof , SCHMIDT, Eva
IPC分类号： C12N15/53 , C12N9/02 , A61K48/00 , C12N5/10
CPC分类号： A61K38/44 , A61K31/341 , A61K35/17 , A61K48/005 , C12N7/00 , C12N9/0071 , C12N9/0079 , C12N15/86 , C12N2740/17032 , C12N2740/17043 , C12N2740/17052 , C12N2999/007 , C12Y114/14001
摘要： The invention relates to a modified human CYP4B1 protein and a nucleic acid encoding for the modified human CYP4B1 protein. The invention further relates to an expression vector comprising a nucleic acid encoding for a modified human CYP4B1 protein, as well as to a cell comprising a modified CYP4B1 protein. In addition, the invention relates to a modified human CYP4B1 protein for use in treating transplantation induced graft- versus-host-disease (GvHD), and to 4-ipomeanol (4-IPO) for use in killing a cell.
摘要翻译：本发明涉及修饰的人CYP4B1蛋白和编码修饰的人CYP4B1蛋白的核酸。本发明还涉及包含编码修饰的人CYP4B1蛋白的核酸以及包含修饰的CYP4B1蛋白的细胞的表达载体。此外，本发明涉及用于治疗移植诱导的移植物抗宿主病（GvHD）的修饰的人CYP4B1蛋白和用于杀死细胞的4-异麦芽糖醇（4-IPO）。

3. 发明申请

WO2020101828A2 MODULAR EXPRESSION SYSTEMS FOR GENE EXPRESSION AND METHODS OF USING SAME 审中-公开
公开(公告)号：WO2020101828A2
公开(公告)日：2020-05-22
申请号：PCT/US2019/055808
申请日：2019-10-11
申请人： CHILDREN'S HOSPITAL MEDICAL CENTER , HANENBERG, Helmut
发明人： HANENBERG, Helmut , ANDREASSEN, Paul, R.
IPC分类号： C12N15/86
摘要： Disclosed herein are compositions and methods for the expression of a gene of interest. The disclosed methods may employ codon-optimization and introduction of non-endogenous restriction sites for efficient expression of a gene. The methods may further employ introduction of a gene variant of interest, such that the disclosed methods, compositions, and systems may be used to determine the significance of a variant of interest. Further disclosed are compositions, systems, and methods for the characterization of gene variants, and other mutations that may impact the function of the protein of interest.

4. 发明申请

WO2010111608A1 FOAMYVIRUS VECTORS AND METHODS OF USE 审中-公开
标题翻译： FOAMYVIRUS矢量和使用方法
公开(公告)号：WO2010111608A1
公开(公告)日：2010-09-30
申请号：PCT/US2010/028854
申请日：2010-03-26
申请人： INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION , RETHWILM, Axel , LINDEMANN, Dirk , HANENBERG, Helmut , CLAPP, D., Wade
发明人： RETHWILM, Axel , LINDEMANN, Dirk , HANENBERG, Helmut , CLAPP, D., Wade
IPC分类号： A61K31/7088 , C12N15/63
CPC分类号： A61K31/7088 , C12N15/86 , C12N2740/17043 , C12N2740/17052
摘要： The disclosure of the present application provides foamyvirus vectors, as well as methods and kits involving the same. In at least one embodiment, a plurality of recombinant vectors comprises an expression sequence encoding at least one component of a foamyvirus particle, wherein at least one codon of the expression sequence is optimized for expression in homo sapiens.
摘要翻译：本申请的公开内容提供泡沫病毒载体，以及涉及其的方法和试剂盒。在至少一个实施方案中，多个重组载体包含编码泡沫病毒颗粒的至少一种组分的表达序列，其中表达序列的至少一个密码子被优化用于在智人中表达。

5. 发明申请

WO2013083552A1 INHIBITION OF CIS-PLATIN INDUCED OTOTOXICITY 审中-公开
标题翻译：抑制CIS-PLATIN诱导的毒性
公开(公告)号：WO2013083552A1
公开(公告)日：2013-06-13
申请号：PCT/EP2012/074338
申请日：2012-12-04
申请人： THOMALE, Jürgen , HANENBERG, Helmut
发明人： THOMALE, Jürgen , MENDUS, Diana
IPC分类号： A61K31/138 , A61P27/16 , A61P39/00 , G01N33/15
CPC分类号： A61K31/138
摘要： The invention describes diphenylhydramine (DPH) for treating ototoxicity in a subject, for inhibiting the formation of platinum adducts in a cell of the inner ear, and for preventing and/or inhibiting structural and functional damage in the inner ear. Furthermore, the invention describes an in vitro method for determining a subject's susceptibility for platinum induced ototoxicity and/or platinum induced nephrotoxicity and an in vitro method for screening a compound for inhibiting ototoxicity induced by a platinum complex as well as a kit useful for screening. The invention also describes a composition for treating cancer and concurrently inhibiting ototoxicity, nephrotoxicity and/or neurotoxicity. The invention further describes DPH for treating nephrotoxicity in a subject induced by a medication comprising a platinum complex.
摘要翻译：本发明描述了用于治疗受试者的耳毒性的二苯海拉明（DPH），用于抑制内耳细胞中铂加合物的形成，以及用于预防和/或抑制内耳中的结构和功能损伤。此外，本发明描述了用于确定受试者铂诱导的耳毒性和/或铂诱导的肾毒性的易感性的体外方法，以及用于筛选用于抑制由铂络合物引起的耳毒性的化合物以及用于筛选的试剂盒的体外方法。本发明还描述了用于治疗癌症并同时抑制耳毒性，肾毒性和/或神经毒性的组合物。本发明还描述了用于治疗由包含铂络合物的药物诱导的受试者的肾毒性的DPH。

6. 发明申请

WO2011124725A1 RAD51C AS A HUMAN CANCER SUSCEPTIBILITY GENE 审中-公开
标题翻译： RAD51C作为人类癌症可疑基因
公开(公告)号：WO2011124725A1
公开(公告)日：2011-10-13
申请号：PCT/EP2011/055651
申请日：2011-04-11
申请人： HANENBERG, Helmut , HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF , UNIVERSITÄT ZU KÖLN , NIEDERACHER, Dieter , SCHECKENBACH, Kathrin , SCHMUTZLER, Rita , MEINDL, Alfons , WIEK, Constanze , ERVEN, Verena , FREUND, Marcel
发明人： HANENBERG, Helmut , NIEDERACHER, Dieter , SCHECKENBACH, Kathrin , SCHMUTZLER, Rita , MEINDL, Alfons , WIEK, Constanze , ERVEN, Verena , FREUND, Marcel
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： The invention discloses in vitro methods and a system for determining a predisposition of a subject for developing a cancer on the basis of analyzing a sample of the subject for an alteration of at least one allele of the RAD51C gene. Further disclosed are in vitro methods for assessing clinical features or a pathological progression of a cancer and for assessing at least one RAD51 C gene alteration in a cell. In addition a kit for determining a predisposition of a subject for developing a cancer, and certain uses of oligonucleotides for determining the presence of at least one mono-allelic germ-line mutation of the RAD51C gene.
摘要翻译：本发明公开了体外方法和系统，用于在分析用于RAD51C基因的至少一个等位基因的改变的受试者样品的基础上确定受试者的发展癌症倾向。进一步公开的是用于评估癌症的临床特征或病理进展以及用于评估细胞中至少一种RAD51C基因改变的体外方法。此外，用于确定受试者用于开发癌症的易感性的试剂盒以及确定存在RAD51C基因的至少一种单等位基因种系突变的寡核苷酸的某些用途。

7. 发明申请

WO2010066884A1 METHOD FOR ANALYSIS OF NUCLEIC ACID POPULATIONS 审中-公开
标题翻译：核酸人口分析方法
公开(公告)号：WO2010066884A1
公开(公告)日：2010-06-17
申请号：PCT/EP2009/066945
申请日：2009-12-11
申请人： FEBIT HOLDING GMBH , BEIER, Markus , STÄHLER, Peer F. , STÄHLER, Cord F. , SUMMERER, Daniel , LEONARD, Jack T. , BAU, Stephan , CARUSO, Anthony , SCHRACKE, Nadine , KELLER, Andreas , HANENBERG, Helmut , ECKERMANN, Olaf
发明人： BEIER, Markus , STÄHLER, Peer F. , STÄHLER, Cord F. , SUMMERER, Daniel , LEONARD, Jack T. , BAU, Stephan , CARUSO, Anthony , SCHRACKE, Nadine , KELLER, Andreas , HANENBERG, Helmut , ECKERMANN, Olaf
IPC分类号： C12N15/10 , C12Q1/68
CPC分类号： C12Q1/6834 , C12N15/1006 , C12Q1/6806 , C12Q2565/518 , C12Q2525/191
摘要： The invention relates to a method for isolation of target molecules from a nucleic acid population.
摘要翻译：本发明涉及从核酸群体分离靶分子的方法。

8. 发明申请

WO0140461A3 CDNA SEQUENCE OF TWO INTERACTORS FANCIP4 AND FANCIP5 OF THE FANCONI ANAEMIA PROTEINS OF THE COMPLEMENTATION GROUPS A AND C 审中-公开
标题翻译：两个演员INTER FANCIP4 AND A和C的FANCIP5范科尼贫血互补蛋白的cDNA序列
公开(公告)号：WO0140461A3
公开(公告)日：2002-06-20
申请号：PCT/EP0012197
申请日：2000-12-05
申请人： MULTIGENE BIOTECH GMBH , GROSS HANS JOACHIM , REUTER TANJA , HANENBERG HELMUT , HERTERICH SABINE , WAGNER MATTHIAS , HOEHN HOLGER
发明人： GROSS HANS JOACHIM , REUTER TANJA , HANENBERG HELMUT , HERTERICH SABINE , WAGNER MATTHIAS , HOEHN HOLGER
IPC分类号： A61K48/00 , C07K14/47 , C12N15/12 , A01K67/027 , A61K38/17 , C07K16/18 , C12N15/11 , C12Q1/68 , G01N33/68
CPC分类号： C07K14/47 , A61K48/00
摘要： The present invention relates to the cDNAs of two interactors (FANCIP4 and FANCIP5) of the Fanconi anaemia protein of the complementation groups A and C (FANCA and FANCC) and the corresponding encoded polypeptides and proteins. The invention also relates to the corresponding genes, antibodies directed against the proteins, FANCIP4- or FANCIP5-transgenic organisms and cells as well as to the use of FANCIP4 or FANCIP5 for effector screening. The invention further relates to the pharmaceutical use of the inventive nucleic acids, polypeptides, proteins and antibodies.
摘要翻译：本发明涉及到蛋白质A的范可尼贫血互补两个交互件（FANCIP4 AND FANCIP5）的cDNA的和C（FANCA和FANCC）以及由此编码的多肽和蛋白质。进一步的目的是针对这些蛋白质的抗体的相应基因，或FANCIP4- FANCIP5转基因生物和细胞，以及用于执行筛选和药物用途的核酸，多肽，蛋白质和抗体的使用或FANCIP4的FANCIP5 ，

9. 发明申请

WO0100822A3 CDNA SEQUENCES OF TWO INTERACTING FANCIP2 AND FANCIP3 OF THE FANCONI ANEMIA COMPLEMENTATION GROUP A PROTEIN 审中-公开
标题翻译：的cDNA序列的两个INTER演员和FANCIP2 FANCIP3的范可尼贫血互补组的蛋白质
公开(公告)号：WO0100822A3
公开(公告)日：2001-07-05
申请号：PCT/EP0005878
申请日：2000-06-26
申请人： MULTIGENE BIOTECH GMBH , GROSS HANS JOACHIM , REUTER TANJA , HANENBERG HELMUT , HERTERICH SABINE , WAGNER MATTHIAS
发明人： GROSS HANS JOACHIM , REUTER TANJA , HANENBERG HELMUT , HERTERICH SABINE , WAGNER MATTHIAS
IPC分类号： A01K67/027 , A61K31/7088 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P7/06 , A61P35/00 , A61P43/00 , C07K14/47 , C07K16/18 , C12N5/10 , C12N15/09 , C12N15/12 , C12P21/00 , C12Q1/02 , G01N33/15 , G01N33/50 , G01N33/53 , G01N33/566 , A61K38/17 , C12N15/63 , C12Q1/68 , G01N33/68
CPC分类号： C07K14/47 , A01K2217/05 , A61K38/00
摘要： The invention relates to the cDNA sequences of two interactors (FANCIP2 and FANCIP3) of the Fanconi anemia complementation group A (FANCA) protein and the corresponding encoded proteins. The invention also relates to the corresponding genes, to the antibodies directed to said proteins, to FANCIP2- or FANCIP3-transgenic organisms and cells and to the use of FANCIP2 and FANCIP3 for effector screening and to the pharmaceutical application of the inventive nucleic acids, proteins and antibodies.
摘要翻译：本发明涉及范可尼贫血互补组蛋白A（FANCA）两个交互件（FANCIP2和FANCIP3）的cDNA的，以及其中编码的蛋白质。进一步的目的是针对这些蛋白质的抗体的相应基因，或FANCIP2- FANCIP3转基因生物和细胞，以及用于执行筛选和药物用途的核酸，蛋白质和抗体的使用或FANCIP2的FANCIP3。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式